Alain M. Gardier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alain M. Gardier has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
D.J. David
7 shared publicationsChristian Jacquot
Laboratoire de Neuropharmacologie UPRES EAD MENRT, Faculté de Pharmacie IFR-ISIT Institut de Signalisation et Innovation Thérapeutique, Université Paris-Sud, F92296 Châtenay-Malabry Cedex, France
4 shared publications- Denis Joseph David
Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP‐Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan Université Paris‐Saclay, UVSQ Orsay France
4 shared publications J.P. Guilloux
3 shared publicationsMichel Bourin
Laboratoire de Neuropharmacologie EA 3544, Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry Cedex, France
3 shared publicationsA.C. Petit
2 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S262
P.1.g.046 Neuronal circuits involved in vortioxetine-improved pattern separation in mice: role of the serotonin1B (5-HT1B) receptor
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S262
P.1.g.046 Neuronal circuits involved in vortioxetine-improved pattern separation in mice: role of the serotonin1B (5-HT1B) receptor
- 1 March 2015
- Published by Elsevier in Brain Stimulation
- Vol. 8 (2) , 385
Electroconvulsive treatment requires adult neurogenesis to rescue behavior in a mouse model of stress-induced depression
- 1 March 2015
- Published by Elsevier in Brain Stimulation
- Vol. 8 (2) , 385
Electroconvulsive treatment requires adult neurogenesis to rescue behavior in a mouse model of stress-induced depression
- 1 October 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24, S365
P.2.a.007 5-HT1B receptors play a key role in modulation of pattern separation performance and hedonic state of old mice
- 1 October 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24, S365
P.2.a.007 5-HT1B receptors play a key role in modulation of pattern separation performance and hedonic state of old mice
- 1 October 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23
S.12.07 Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response
- 1 October 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23
S.12.07 Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response
- 1 March 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23, S18-S19
P.1.019 Role of the 5-HT2A receptor in the mechanism of action of antidepressant drugs: a translational human–mouse study
- 1 March 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23, S18-S19
P.1.019 Role of the 5-HT2A receptor in the mechanism of action of antidepressant drugs: a translational human–mouse study
- Open Access
- 2 May 2012
- Published by IntechOpen
Non-Response to Initial Antidepressant Therapy
Non-Response to Initial Antidepressant Therapy | InTechOpen, Published on: 2012-05-02. Authors: J.P. Guilloux, D.J. David, B.A. Samuels, et
- 2 May 2012
- Published by IntechOpen
Open AccessNon-Response to Initial Antidepressant Therapy
Non-Response to Initial Antidepressant Therapy | InTechOpen, Published on: 2012-05-02. Authors: J.P. Guilloux, D.J. David, B.A. Samuels, et
- 1 April 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (7) , 883-892
5‐HT4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice
Background and purpose: A strategy to treat Alzheimer's disease (AD) is to increase the soluble form of amyloid precursor protein (sAPPα), a promnesic protein, in the brain. Because strong evidence supports beneficial effects of 5‐hydroxytryptamine 5‐HT4 receptor agonists in memory and learning, we investigated the role of 5‐HT4 receptors on APP processing in 8 weeks‐old male C57BL/6j mice.Experimental approach: Mice were given, subcutaneously, prucalopride or ML 10302 (s.c.), two highly selective 5‐HT4 receptor agonists and, up to 240 min later, the hippocampus and cortex were analysed by Western blot for sAPPα determination.Key results: Prucalopride (5 or 10 mg kg‐1) significantly increased sAPPα levels in the hippocampus and cortex, but did not modify the expression level of APP mRNA as detected by quantitative RT‐PCR. A selective 5‐HT4 receptor antagonist, GR125487 (1 mg kg‐1, s.c.) inhibited prucalopride induced‐ increase in sAPPα levels. In addition, levels of sAPPα were increased by ML10302 only at 20 mg kg‐1 and was limited to the cortex. Also, prucalopride increased sAPPα levels in the cortex of a transgenic mouse model of AD, expressing the London mutation of APP. Furthermore, the combined injection of a selective acetylcholinesterase inhibitor, donepezil and prucalopride induced a synergic increase in sAPPα levels in the cortex and hippocampus.Conclusions and implications: Our results demonstrate that the 5‐HT4 receptor plays a key role in the non‐amyloidogenic pathway of APP metabolism in vivo and give support to the beneficial use of 5‐HT4 agonists for AD treatment.British Journal of Pharmacology (2007) 150, 883–892. doi:10.1038/sj.bjp.0707178
- 1 April 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (7) , 883-892
5‐HT4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice
Background and purpose: A strategy to treat Alzheimer's disease (AD) is to increase the soluble form of amyloid precursor protein (sAPPα), a promnesic protein, in the brain. Because strong evidence supports beneficial effects of 5‐hydroxytryptamine 5‐HT4 receptor agonists in memory and learning, we investigated the role of 5‐HT4 receptors on APP processing in 8 weeks‐old male C57BL/6j mice.Experimental approach: Mice were given, subcutaneously, prucalopride or ML 10302 (s.c.), two highly selective 5‐HT4 receptor agonists and, up to 240 min later, the hippocampus and cortex were analysed by Western blot for sAPPα determination.Key results: Prucalopride (5 or 10 mg kg‐1) significantly increased sAPPα levels in the hippocampus and cortex, but did not modify the expression level of APP mRNA as detected by quantitative RT‐PCR. A selective 5‐HT4 receptor antagonist, GR125487 (1 mg kg‐1, s.c.) inhibited prucalopride induced‐ increase in sAPPα levels. In addition, levels of sAPPα were increased by ML10302 only at 20 mg kg‐1 and was limited to the cortex. Also, prucalopride increased sAPPα levels in the cortex of a transgenic mouse model of AD, expressing the London mutation of APP. Furthermore, the combined injection of a selective acetylcholinesterase inhibitor, donepezil and prucalopride induced a synergic increase in sAPPα levels in the cortex and hippocampus.Conclusions and implications: Our results demonstrate that the 5‐HT4 receptor plays a key role in the non‐amyloidogenic pathway of APP metabolism in vivo and give support to the beneficial use of 5‐HT4 agonists for AD treatment.British Journal of Pharmacology (2007) 150, 883–892. doi:10.1038/sj.bjp.0707178
- 25 January 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (10) , 2162-2172
Blockade of 5-HT1A Receptors by (±)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT1A Receptor Knockout Mice
Selective serotonin reuptake inhibitors like paroxetine (Prx) often requires 4–6 weeks to achieve clinical benefits in depressed patients. Pindolol shortens this delay and it has been suggested that this effect is mediated by somatodendritic 5-hydroxytryptamine (5-HT) 1A autoreceptors. However clinical data on the beneficial effects of pindolol are conflicting. To study the effects of ()-pindolol–paroxetine administration, we used genetical and pharmacological approaches in 5-HT1A knockout mice (5-HT1A-/-). Two assays, in vivo intracerebral microdialysis in awake mice and the forced swimming test (FST), were used to assess the antidepressant-like effects of this drug combination. Basal levels of extracellular serotonin, 5-HT ([5-HT]ext) in the frontal cortex (FCX) and the dorsal raphe nucleus (DRN) did not differ between the two strains of mice, suggesting a lack of tonic control of 5-HT1A autoreceptors on nerve terminal 5-HT release. Prx (1 and 4 mg/kg) dose-dependently increased cortical [5-HT]ext in both genotypes, but the effects were greater in mutants. The selective 5-HT1A receptor antagonist, WAY-100635 (0.5 mg/kg), or ()-pindolol (5 and 10 mg/kg) potentiated the effects of Prx (4 mg/kg) on cortical [5-HT]ext in 5-HT1A+/+, but not in 5-HT1A-/- mice. Similar responses were obtained following local intra-raphe perfusion by reverse microdialysis of either WAY-100635 or ()-pindolol (100 M each). In the FST, Prx administration dose-dependently decreased the immobility time in both strains of mice, but the response was much greater in 5HT1A-/- mice. In contrast, ()-pindolol blocked Prx-induced decreases in the immobility time while WAY-100635 had no effect in both genotypes. These findings using 5-HT1A-/- mice confirm that ()-pindolol behaves as an antagonist of 5-HT1A autoreceptor in mice, but its blockade of paroxetine-induced antidepressant-like effects in the FST may be due to its binding to other neurotransmitter receptors.
- 25 January 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (10) , 2162-2172
Blockade of 5-HT1A Receptors by (±)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT1A Receptor Knockout Mice
Selective serotonin reuptake inhibitors like paroxetine (Prx) often requires 4–6 weeks to achieve clinical benefits in depressed patients. Pindolol shortens this delay and it has been suggested that this effect is mediated by somatodendritic 5-hydroxytryptamine (5-HT) 1A autoreceptors. However clinical data on the beneficial effects of pindolol are conflicting. To study the effects of ()-pindolol–paroxetine administration, we used genetical and pharmacological approaches in 5-HT1A knockout mice (5-HT1A-/-). Two assays, in vivo intracerebral microdialysis in awake mice and the forced swimming test (FST), were used to assess the antidepressant-like effects of this drug combination. Basal levels of extracellular serotonin, 5-HT ([5-HT]ext) in the frontal cortex (FCX) and the dorsal raphe nucleus (DRN) did not differ between the two strains of mice, suggesting a lack of tonic control of 5-HT1A autoreceptors on nerve terminal 5-HT release. Prx (1 and 4 mg/kg) dose-dependently increased cortical [5-HT]ext in both genotypes, but the effects were greater in mutants. The selective 5-HT1A receptor antagonist, WAY-100635 (0.5 mg/kg), or ()-pindolol (5 and 10 mg/kg) potentiated the effects of Prx (4 mg/kg) on cortical [5-HT]ext in 5-HT1A+/+, but not in 5-HT1A-/- mice. Similar responses were obtained following local intra-raphe perfusion by reverse microdialysis of either WAY-100635 or ()-pindolol (100 M each). In the FST, Prx administration dose-dependently decreased the immobility time in both strains of mice, but the response was much greater in 5HT1A-/- mice. In contrast, ()-pindolol blocked Prx-induced decreases in the immobility time while WAY-100635 had no effect in both genotypes. These findings using 5-HT1A-/- mice confirm that ()-pindolol behaves as an antagonist of 5-HT1A autoreceptor in mice, but its blockade of paroxetine-induced antidepressant-like effects in the FST may be due to its binding to other neurotransmitter receptors.